melphalan and Inappropriate-ADH-Syndrome

melphalan has been researched along with Inappropriate-ADH-Syndrome* in 2 studies

Other Studies

2 other study(ies) available for melphalan and Inappropriate-ADH-Syndrome

Article	Year
L-phenylalanine mustard-dianhydrogalactitol and hyponatremia. Pediatric hematology and oncology, 1986, Volume: 3, Issue:3 The incidence of hyponatremia in 34 patients following administration of high-dose L-phenylalanine mustard (L-PAM) and dianhydrogalactitol (DAG) was determined. Two consecutive daily levels of 133 mEq/l or less were observed in 12 patients. These episodes coincided with the advent of diarrhea about 10-12 days after drug administration. The hyponatremia was not due to the syndrome of inappropriate antidiuretic hormone secretion. Topics: Diagnosis, Differential; Dianhydrogalactitol; Diarrhea; Humans; Hyponatremia; Inappropriate ADH Syndrome; Melphalan; Nervous System Neoplasms; Neuroblastoma; Prospective Studies	1986
Syndrome of inappropriate antidiuretic hormone secretion. A complication of high-dose intravenous melphalan. Cancer, 1985, Jan-01, Volume: 55, Issue:1 Melphalan is now being investigated as an intravenous (IV) bolus chemotherapeutic agent in children with resistant tumors involving the bone marrow. Two patients received 2 mg/kg melphalan, IV bolus; 10 patients received 1 mg/kg. Seven of the ten patients receiving 1 mg/kg had noticeable downward trends in the serum sodium concentrations, whereas both patients receiving 2 mg/kg developed hyponatremia (serum sodium concentration [SNa], mEq/l = 124-125) and inappropriate urinary sodium losses. Syndrome of inappropriate antidiuretic hormone (SiADH) is a previously unreported complication of high dose bolus melphalan therapy. Topics: Adolescent; Child; Female; Humans; Inappropriate ADH Syndrome; Injections, Intravenous; Male; Melphalan; Neoplasms; Sodium	1985

Article

Year

L-phenylalanine mustard-dianhydrogalactitol and hyponatremia.

Pediatric hematology and oncology, 1986, Volume: 3, Issue:3

The incidence of hyponatremia in 34 patients following administration of high-dose L-phenylalanine mustard (L-PAM) and dianhydrogalactitol (DAG) was determined. Two consecutive daily levels of 133 mEq/l or less were observed in 12 patients. These episodes coincided with the advent of diarrhea about 10-12 days after drug administration. The hyponatremia was not due to the syndrome of inappropriate antidiuretic hormone secretion.

Topics: Diagnosis, Differential; Dianhydrogalactitol; Diarrhea; Humans; Hyponatremia; Inappropriate ADH Syndrome; Melphalan; Nervous System Neoplasms; Neuroblastoma; Prospective Studies

1986

Syndrome of inappropriate antidiuretic hormone secretion. A complication of high-dose intravenous melphalan.

Cancer, 1985, Jan-01, Volume: 55, Issue:1

Melphalan is now being investigated as an intravenous (IV) bolus chemotherapeutic agent in children with resistant tumors involving the bone marrow. Two patients received 2 mg/kg melphalan, IV bolus; 10 patients received 1 mg/kg. Seven of the ten patients receiving 1 mg/kg had noticeable downward trends in the serum sodium concentrations, whereas both patients receiving 2 mg/kg developed hyponatremia (serum sodium concentration [SNa], mEq/l = 124-125) and inappropriate urinary sodium losses. Syndrome of inappropriate antidiuretic hormone (SiADH) is a previously unreported complication of high dose bolus melphalan therapy.

Topics: Adolescent; Child; Female; Humans; Inappropriate ADH Syndrome; Injections, Intravenous; Male; Melphalan; Neoplasms; Sodium

1985